BIOTERRORBIBLE.

COM: The following news reports are in respect to bio-terror related technology
which was released within the calendar year of 2009. Over the last 5 years, a pandemic blog, a pandemic
Facebook application, multiple bio-terror sniffing phone applications, and a bio-terror first responder
iPhone application have all been invented. All that is currently missing from the pandemic equation is the
made for TV bio-terror attack.
Title: Danish Firm Gets U.S. Contract For Freeze-Dried Smallpox Vaccine
Date: November 19, 2009
Source: Bio Prep Watch
Abstract: The United States will pay the Danish biotechnology firm Bavarian Nordic as much as $40
million to adopt its smallpox vaccine so that it can be freeze-dried.
The contract, which will fund preclinical and clinical studies on efforts to create a freeze-dried version of
Bavarian Nordics Imvamune vaccine, will also be used to validate the new freeze-dried manufacturing
process.
Freeze-dried vaccines can potentially be kept longer than those in a liquid form that must be frozen for
storage, Bavarian Nordic said. The freeze-drying process also allows for the government to overcome the
challenges it faces from cold-chain logistics and storage.
The freeze-drying development activities will be researched in tandem with licensure activities for the
current liquid form of Imvamune.
While smallpox is no longer found in the world, it has been identified as a top bioterrorism threat.
Thirty-three percent of the funding will go to fund the first year of the project with an option of additional
funding if certain pre-determined technical milestones are met.
We are excited about receiving yet another contract from the US Government in support for the
development of an advanced freeze-dried version of our Imvamune smallpox vaccine, Anders
Hedegaard, president and CEO of Bavarian Nordic, said. It clearly demonstrates the continued
commitment from the U.S. government to support the development of advanced medical
countermeasures and it strengthens our confidence that the option to procure up to an additional 60
million doses of Imvamune under the ongoing RFP-3 contract will be exercised (Bio Prep Watch, 2009).